Meridian Bioscience, Inc. (VIVO) Forms $14.20 Double Top; Ecor1 Capital Has Boosted Dicerna Pharmaceuticals (DRNA) Position By $950,000

Ecor1 Capital Llc increased Dicerna Pharmaceuticals Inc (DRNA) stake by 24.74% reported in 2017Q3 SEC filing. Ecor1 Capital Llc acquired 190,000 shares as Dicerna Pharmaceuticals Inc (DRNA)’s stock rose 12.37%. The Ecor1 Capital Llc holds 957,992 shares with $5.51M value, up from 767,992 last quarter. Dicerna Pharmaceuticals Inc now has $475.59M valuation. The stock increased 6.21% or $0.54 during the last trading session, reaching $9.24. About 583,651 shares traded or 103.32% up from the average. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has declined 5.22% since December 28, 2016 and is downtrending. It has underperformed by 21.92% the S&P500.

Meridian Bioscience, Inc. (VIVO) formed double top with $14.77 target or 4.00% above today’s $14.20 share price. Meridian Bioscience, Inc. (VIVO) has $600.77M valuation. The stock decreased 0.35% or $0.05 during the last trading session, reaching $14.2. About 141,612 shares traded. Meridian Bioscience, Inc. (NASDAQ:VIVO) has declined 26.84% since December 28, 2016 and is downtrending. It has underperformed by 43.54% the S&P500.

Analysts await Meridian Bioscience, Inc. (NASDAQ:VIVO) to report earnings on January, 24. They expect $0.14 EPS, down 6.67% or $0.01 from last year’s $0.15 per share. VIVO’s profit will be $5.92 million for 25.36 P/E if the $0.14 EPS becomes a reality. After $0.15 actual EPS reported by Meridian Bioscience, Inc. for the previous quarter, Wall Street now forecasts -6.67% negative EPS growth.

Investors sentiment increased to 1.37 in Q3 2017. Its up 0.02, from 1.35 in 2017Q2. It increased, as 12 investors sold Meridian Bioscience, Inc. shares while 42 reduced holdings. 24 funds opened positions while 50 raised stakes. 36.26 million shares or 2.14% more from 35.50 million shares in 2017Q2 were reported. D E Shaw & Co reported 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). First Trust Advisors L P reported 0% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO). Moreover, Principal Group Inc has 0% invested in Meridian Bioscience, Inc. (NASDAQ:VIVO). Manufacturers Life Ins Co The has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Moreover, Victory Mgmt Inc has 0% invested in Meridian Bioscience, Inc. (NASDAQ:VIVO) for 30,753 shares. Voya Investment Mngmt Ltd owns 22,186 shares for 0% of their portfolio. Renaissance Ltd Co holds 0.03% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO) for 2.05 million shares. Mason Street Advisors Ltd Liability owns 10,689 shares or 0% of their US portfolio. Greylin Invest Mangement Incorporated holds 0.24% or 72,335 shares in its portfolio. Horan Advsr Limited Liability has invested 0% of its portfolio in Meridian Bioscience, Inc. (NASDAQ:VIVO). Alliancebernstein Limited Partnership has 0% invested in Meridian Bioscience, Inc. (NASDAQ:VIVO) for 79,337 shares. Bancshares Of Montreal Can has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). The New Jersey-based State Of New Jersey Common Pension Fund D has invested 0% in Meridian Bioscience, Inc. (NASDAQ:VIVO). Riverpoint Cap Management Lc reported 24,985 shares. Highbridge Mgmt Ltd Co holds 0% or 15,594 shares.

Among 5 analysts covering Meridian Bioscience (NASDAQ:VIVO), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Meridian Bioscience has $23 highest and $9.0 lowest target. $17.60’s average target is 23.94% above currents $14.2 stock price. Meridian Bioscience had 10 analyst reports since July 28, 2015 according to SRatingsIntel. Piper Jaffray maintained Meridian Bioscience, Inc. (NASDAQ:VIVO) on Thursday, September 21 with “Sell” rating. The firm earned “Neutral” rating on Monday, March 21 by Hilliard Lyons. Robert W. Baird maintained it with “Hold” rating and $15.0 target in Thursday, October 19 report. The stock has “Hold” rating by Canaccord Genuity on Thursday, September 10. Piper Jaffray maintained Meridian Bioscience, Inc. (NASDAQ:VIVO) rating on Thursday, July 27. Piper Jaffray has “Sell” rating and $900 target. The firm has “Buy” rating given on Monday, March 28 by Hilliard Lyons. Piper Jaffray maintained the stock with “Sell” rating in Thursday, October 19 report.

Since December 18, 2017, it had 1 buy, and 0 insider sales for $2.00 million activity. $2.00M worth of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) was bought by Bain Capital Life Sciences Investors – LLC.

Among 5 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Dicerna Pharmaceuticals had 17 analyst reports since August 7, 2015 according to SRatingsIntel. The company was maintained on Monday, August 15 by Chardan Capital Markets. The rating was initiated by H.C. Wainwright on Monday, December 12 with “Buy”. The company was maintained on Thursday, June 30 by Stifel Nicolaus. Cowen & Co initiated the stock with “Outperform” rating in Tuesday, September 8 report. The firm has “Neutral” rating given on Thursday, June 30 by Chardan Capital Markets. The rating was maintained by Stifel Nicolaus with “Buy” on Tuesday, May 10. The stock has “Buy” rating by Cowen & Co on Wednesday, August 16. Stifel Nicolaus maintained the shares of DRNA in report on Thursday, November 2 with “Buy” rating. The firm has “Buy” rating given on Tuesday, July 18 by Cowen & Co. The firm has “Hold” rating by Chardan Capital Markets given on Friday, August 11.

Investors sentiment increased to 0.79 in Q3 2017. Its up 0.24, from 0.55 in 2017Q2. It improved, as 9 investors sold DRNA shares while 10 reduced holdings. 8 funds opened positions while 7 raised stakes. 10.37 million shares or 6.06% less from 11.04 million shares in 2017Q2 were reported. Moreover, Eventide Asset Management Limited Liability Corp has 0.12% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 377,000 shares. 683 Capital Limited stated it has 0.46% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Moreover, Vanguard Grp Inc has 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 436,665 shares. The New York-based Art Limited Liability Corp has invested 0.01% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Goldman Sachs Gp Incorporated accumulated 105,420 shares or 0% of the stock. Connor Clark And Lunn Mgmt Limited owns 68,975 shares. Millennium Mgmt Ltd Liability Corp accumulated 27,559 shares or 0% of the stock. Virtu Fin Ltd Liability Corp has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). The California-based Palo Alto Investors has invested 0.12% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Ra Cap Mngmt Ltd Co reported 1.26% stake. Northern Trust owns 36,010 shares. Fmr owns 1.47M shares for 0% of their portfolio. Illinois-based Group One Trading LP has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Bancshares Of America De holds 0% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 397 shares. Panagora Asset Management Incorporated reported 4,318 shares.